Hepatitis Delta Virus and Hepatocellular Carcinoma

Overview

Journal Pathogens

Date 2024 May 24

PMID 38787214

Authors

Daniele Lombardo

Maria Stella Franze

Giuseppe Caminiti

Teresa Pollicino

Affiliations

Soon will be listed here.

Abstract

The hepatitis D virus (HDV) is a compact, enveloped, circular RNA virus that relies on hepatitis B virus (HBV) envelope proteins to initiate a primary infection in hepatocytes, assemble, and secrete new virions. Globally, HDV infection affects an estimated 12 million to 72 million people, carrying a significantly elevated risk of developing cirrhosis, liver failure, and hepatocellular carcinoma (HCC) compared to an HBV mono-infection. Furthermore, HDV-associated HCC often manifests at a younger age and exhibits more aggressive characteristics. The intricate mechanisms driving the synergistic carcinogenicity of the HDV and HBV are not fully elucidated but are believed to involve chronic inflammation, immune dysregulation, and the direct oncogenic effects of the HDV. Indeed, recent data highlight that the molecular profile of HCC associated with HDV is unique and distinct from that of HBV-induced HCC. However, the question of whether the HDV is an oncogenic virus remains unanswered. In this review, we comprehensively examined several crucial aspects of the HDV, encompassing its epidemiology, molecular biology, immunology, and the associated risks of liver disease progression and HCC development.

Citing Articles

Histopathological Features of Hepatocellular Carcinoma in Patients with Hepatitis B and D Virus Infection: A Single-Institution Study in Mongolia.

Jargalsaikhan O, Shao W, Ichimura-Shimizu M, Ishimaru S, Koma T, Nomaguchi M Cancers (Basel). 2025; 17(3).

PMID: 39941800 PMC: 11815750. DOI: 10.3390/cancers17030432.

Prevalence, Risk Factors, and Clinical Profiles of Hepatitis D Virus in Nigeria: A Systematic Review, 2009-2024.

Adepoju V, Udah D, Adnani Q Viruses. 2024; 16(11).

PMID: 39599836 PMC: 11598852. DOI: 10.3390/v16111723.

References

Karimzadeh H, Kiraithe M, Kosinska A, Glaser M, Fiedler M, Oberhardt V . Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 T Cells. J Virol. 2018; 92(13). PMC: 6002722. DOI: 10.1128/JVI.01891-17. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Atsama Amougou M, Noah Noah D, Moundipa P, Pineau P, Njouom R . A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis. 2016; 16(1):647. PMC: 5100184. DOI: 10.1186/s12879-016-1992-2. View

McNair A, Cheng D, MONJARDINO J, Thomas H, Kerr I . Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol. 1994; 75 ( Pt 6):1371-8. DOI: 10.1099/0022-1317-75-6-1371. View

Kang Y, Hong S, Lee H, Kim W . Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol. 2005; 35(11):1340-6. DOI: 10.1016/j.humpath.2004.07.021. View

Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S . Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020; 72(4):1177-1190. DOI: 10.1002/hep.31214. View

Giannini E, Pasta A, Pieri G, Torres M, Marseglia M, Pelizzaro F . Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma. Liver Int. 2024; 44(7):1588-1599. DOI: 10.1111/liv.15855. View

Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G . Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010; 52(5):658-64. DOI: 10.1016/j.jhep.2009.10.036. View

10.

Chen X, Oidovsambuu O, Liu P, Grosely R, Elazar M, Winn V . A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology. 2016; 66(6):1739-1749. PMC: 5441964. DOI: 10.1002/hep.28957. View

11.

Raimondo G, Brunetto M, Pontisso P, Smedile A, Maina A, Saitta C . Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2005; 43(1):100-7. DOI: 10.1002/hep.20944. View

12.

Hwang S, Park K . Cell cycle arrest mediated by hepatitis delta antigen. FEBS Lett. 1999; 449(1):41-4. DOI: 10.1016/s0014-5793(99)00394-4. View

13.

Jang T, Wei Y, Liu T, Yeh M, Liu S, Hsu C . Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep. 2021; 11(1):8184. PMC: 8047028. DOI: 10.1038/s41598-021-87679-w. View

14.

Suarez-Amaran L, Usai C, di Scala M, Godoy C, Ni Y, Hommel M . A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction. J Hepatol. 2017; 67(4):669-679. DOI: 10.1016/j.jhep.2017.05.010. View

15.

Zhang Q, Matsuura K, Kleiner D, Zamboni F, Alter H, Farci P . Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. J Transl Med. 2016; 14(1):328. PMC: 5125040. DOI: 10.1186/s12967-016-1085-4. View

16.

Chida T, Ishida Y, Morioka S, Sugahara G, Han C, Lam B . Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response. JCI Insight. 2023; 8(9). PMC: 10243812. DOI: 10.1172/jci.insight.162404. View

17.

Cross T, Rizzi P, Horner M, Jolly A, Hussain M, Smith H . The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2007; 80(2):277-82. DOI: 10.1002/jmv.21078. View

18.

Beguelin C, Moradpour D, Sahli R, Suter-Riniker F, Luthi A, Cavassini M . Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol. 2016; 66(2):297-303. DOI: 10.1016/j.jhep.2016.10.007. View

19.

Saracco G, Rosina F, Brunetto M, Amoroso P, Caredda F, Farci P . Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol. 1987; 5(3):274-81. DOI: 10.1016/s0168-8278(87)80032-6. View

20.

Yurdaydin C, Idilman R, Bozkaya H, Bozdayi A . Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010; 17(11):749-56. DOI: 10.1111/j.1365-2893.2010.01353.x. View